Quick answers
- What is Brimonidine tartrate and timolol maleate used for?
- The FDA-approved label (Brimonidine Tartrate and Timolol maleate Ophthalmic Solution, Gland Pharma Limited, June 16, 2026) says: “Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution, 0.2%/0.5% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the side effects of Brimonidine tartrate and timolol maleate?
- The “Adverse Reactions” section of the FDA label (Brimonidine Tartrate and Timolol maleate Ophthalmic Solution, Gland Pharma Limited, June 16, 2026) begins: “The following serious adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions [see Contraindications (4.4)] Potential for Severe Respiratory or Cardiac Reactions [see Warnings and Precautions (5.1)] Cardiac Failure [see Warnings and Precautions (5.2)] Potentiation of Vascular Insufficiency [see Warnings and Precautions (5.4)] Increased Reactivity to Allergens [see Warnings and Precautions (5.5)] Potentiation of Muscle Weakness [see Warnings and …” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the drug interactions of Brimonidine tartrate and timolol maleate?
- The “Drug Interactions” section of the FDA label (Brimonidine Tartrate and Timolol maleate Ophthalmic Solution, Gland Pharma Limited, June 16, 2026) begins: “Antihypertensives/cardiac glycosides may lower blood pressure. (7.1) Concomitant use with systemic beta-blockers may potentiate systemic beta-blockade. (7.2) Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (7.3) Catecholamine-depleting drugs may have additive effects and produce hypotension and/or marked bradycardia.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Brimonidine tartrate and timolol maleate have a boxed warning?
- No. None of the 15 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Brimonidine tartrate and timolol maleate?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
- Has Brimonidine tartrate and timolol maleate been recalled?
- FDA enforcement reports list 5 recalls of products of this medicine; the newest started March 5, 2026 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Brimonidine tartrate and timolol maleate?
- 15 companies list prescription products of Brimonidine tartrate and timolol maleate in the FDA NDC Directory, including Caplin Steriles Limited, Somerset Therapeutics, LLC and Gland Pharma Limited.
What Brimonidine tartrate and timolol maleate is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution, 0.2%/0.5% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP. …
— FDA label: Brimonidine Tartrate and Timolol maleate Ophthalmic Solution, Gland Pharma Limited, effective June 16, 2026. Read the full label on DailyMed →
Label quoted: the one for the most common form (solution/ drops, ophthalmic), Brimonidine Tartrate and Timolol maleate Ophthalmic Solution, Gland Pharma Limited; it covers 3 products in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.
The FDA has 15 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 15 FDA labels for this medicine have a boxed warning.
Brimonidine tartrate and timolol maleate side effects
Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.
The following serious adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions [see Contraindications (4.4)] Potential for Severe Respiratory or Cardiac Reactions [see Warnings and Precautions (5.1)] Cardiac Failure [see Warnings and Precautions (5.2)] Potentiation of Vascular Insufficiency [see Warnings and Precautions (5.4)] Increased Reactivity to Allergens [see Warnings and Precautions (5.5)] Potentiation of Muscle Weakness [see Warnings and …
— FDA label: Brimonidine Tartrate and Timolol maleate Ophthalmic Solution, Gland Pharma Limited, effective June 16, 2026. This is part of the section. Read the full label on DailyMed →
Brimonidine tartrate and timolol maleate drug interactions
Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.
Antihypertensives/cardiac glycosides may lower blood pressure. (7.1) Concomitant use with systemic beta-blockers may potentiate systemic beta-blockade. (7.2) Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (7.3) Catecholamine-depleting drugs may have additive effects and produce hypotension and/or marked bradycardia.
Read more of this section
(7.4) Use with CNS depressants may result in an additive or potentiating effect. (7.5) Digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time. (7.6) CYP2D6 inhibitors may potentiate systemic beta-blockade. (7.7) Tricyclic antidepressants may potentially blunt the hypotensive effect of systemic clonidine. (7.8) Monoamine oxidase inhibitors may result in increased hypotension. (7.9) 7.1 Antihypertensives/Cardiac Glycosides Because brimonidine tartrate/timolol maleate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate/timolol maleate ophthalmic solution is advised. 7.2 Beta-adrenergic Blocking Agents Patients who are receiving a beta-adrenergic blocking agent either orally or intravenously and brimonidine tartrate/timolol maleate ophthalmic solution should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended. 7.3 Calcium Antagonists Caution should be used in the co-administration of beta-adrenergic blocking agents, such as brimonidine tartrate/timolol maleate ophthalmic solution, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, and hypotension. In patients with impaired cardiac function, co-administration should be avoided. 7.4 Catecholamine-depleting Drugs Close observation of the patient is recommended when a beta blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension. 7.5 CNS Depressants Although specific drug interaction studies have not been conducted with brimonidine tartrate/timolol maleate ophthalmic solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered. 7.6 Digitalis and Calcium Antagonists The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time. 7.7 CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol. 7.8 Tricyclic Antidepressants Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.
— FDA label: Brimonidine Tartrate and Timolol maleate Ophthalmic Solution, Gland Pharma Limited, effective June 16, 2026. This is part of the section. Read the full label on DailyMed →
Brimonidine tartrate and timolol maleate dosage
Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.
The recommended dosage is one drop in the affected eye(s) twice daily approximately 12 hours apart. If more than one topical ophthalmic product is to be used, the different products should be instilled at least 5 minutes apart. One drop in the affected eye(s), twice daily approximately 12 hours apart.
— FDA label: Brimonidine Tartrate and Timolol maleate Ophthalmic Solution, Gland Pharma Limited, effective June 16, 2026. Read the full label on DailyMed →
Brimonidine tartrate and timolol maleate in pregnancy
Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.
Risk Summary There are no adequate and well-controlled studies with brimonidine tartrate/timolol maleate ophthalmic solution in pregnant women. Limited available data from postmarketing safety reports and published literature reviews with brimonidine tartrate/timolol maleate ophthalmic solution use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes (see Data).
Read more of this section
In animal studies, brimonidine crossed the placenta and entered into the fetal circulation to a limited extent. Oral administration of brimonidine tartrate or timolol maleate to pregnant rats and rabbits during organogenesis at dose exposures 580 and 37 times the recommended human ophthalmic dose (RHOD) resulted in no adverse developmental effects (see Data). Oral administration of timolol maleate to mice, rats, and rabbits during organogenesis at dose exposures up to 4,200 times the RHOD resulted in no evidence of fetal malformations (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Human Data Limited available data from postmarketing safety reports and published literature with topical use of brimonidine ophthalmic solution in pregnant women are insufficient to inform a drug-associated risk of pregnancy-related adverse outcomes including miscarriage, stillbirth, congenital anomaly, and events experienced by the breastfed infant. Animal Data Embryo fetal development studies were conducted with oral administration of brimonidine tartrate during organogenesis in rats (gestation days 6 to 15) and rabbits (gestation days 6 to 18). No adverse developmental effects were observed in rats up to 2.5 mg/kg/day and rabbits up to 5 mg/kg/day. These doses represent exposures 580 and 37 times higher, respectively, than the recommended human ophthalmic dose (RHOD) of brimonidine tartrate/timolol maleate ophthalmic solution at 1 drop in both eyes twice daily. Orally administered brimonidine crossed the placenta in pregnant rats and entered the fetal circulation to a limited extent. Embryofetal development studies conducted with timolol during organogenesis in mice, rats, and rabbits at oral doses up to 50 mg/kg/day [4,200 times the maximum recommended human ophthalmic dose of 0.012 mg/kg/day on a mg/kg basis (MRHOD)] demonstrated no evidence of fetal malformations. Although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. Doses of 1,000 mg/kg/day (83,000 times the MRHOD) were maternotoxic in mice and resulted in an increased number of fetal resorptions. Increased fetal resorptions were also seen in rabbits at doses 8,300 times the MRHOD without apparent maternotoxicity.
— FDA label: Brimonidine Tartrate and Timolol maleate Ophthalmic Solution, Gland Pharma Limited, effective June 16, 2026. Read the full label on DailyMed →
When Brimonidine tartrate and timolol maleate should not be used
Quoted from the “Contraindications” section of the FDA-approved label.
Bronchial asthma, a history of bronchial asthma, severe chronic obstructive pulmonary disease. (4.1, 5.1, 5.3) Sinus bradycardia, atrioventricular block, overt cardiac failure, cardiogenic shock. (4.2, 5.2) Neonates and infants (pediatric patients younger than 2 years old). (4.3) Hypersensitivity to any component of this product.
Read more of this section
(4.4) 4.1 Reactive Airway Disease Including Asthma, COPD Brimonidine tartrate/timolol maleate ophthalmic solution is contraindicated in patients with reactive airway disease including bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease [see Warnings and Precautions (5.1, 5.3)]. 4.2 Sinus Bradycardia, AV Block, Cardiac Failure, Cardiogenic Shock Brimonidine tartrate/timolol maleate ophthalmic solution is contraindicated in patients with sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure [see Warnings and Precautions (5.2)]; cardiogenic shock. 4.3 Neonates and Infants (Pediatric Patients Younger Than 2 Years Old) Brimonidine tartrate/timolol maleate ophthalmic solution is contraindicated in neonates and infants (pediatric patients younger than 2 years old) [see Use in Specific Populations (8.4)]. 4.4 Hypersensitivity Reactions Local hypersensitivity reactions have occurred following the use of different components of brimonidine tartrate/timolol maleate ophthalmic solution. Brimonidine tartrate/timolol maleate ophthalmic solution is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past.
— FDA label: Brimonidine Tartrate and Timolol maleate Ophthalmic Solution, Gland Pharma Limited, effective June 16, 2026. Read the full label on DailyMed →
Brimonidine tartrate and timolol maleate overdose
Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).
There have been reports of inadvertent overdosage with timolol ophthalmic solution resulting in systemic effects similar to those seen with systemic beta-adrenergic blocking agents such as dizziness, headache, shortness of breath, bradycardia, bronchospasm, and cardiac arrest. With the exception of hypotension, very limited information exists on accidental ingestion of brimonidine in adults.
Read more of this section
Symptoms of brimonidine overdose have been reported in neonates, infants, and children receiving brimonidine ophthalmic solutions as part of medical treatment of congenital glaucoma or by accidental oral ingestion [see Use in Specific Populations (8.4)]. Treatment of an oral overdose includes supportive and symptomatic therapy; a patent airway should be maintained.
— FDA label: Brimonidine Tartrate and Timolol maleate Ophthalmic Solution, Gland Pharma Limited, effective June 16, 2026. Read the full label on DailyMed →
Forms and how it is given
| Dosage forms | Solution/ drops · Solution |
|---|---|
| Route | Ophthalmic |
| Prescription products | 21 in the FDA NDC Directory |
| Brand names | Combigan |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| brimonidine tartrate 2 mg/mL · timolol maleate 5 mg/mL solution | Generic | $2.00–$3.16 per mL 11 packages, lowest to highest |
| brimonidine tartrate 2 mg/mL · timolol maleate 5 mg/mL solution/ drops | Generic | $2.00–$3.16 per mL 16 packages, lowest to highest |
| brimonidine tartrate 2 mg/mL · timolol maleate 5 mg/mL solution/ drops | Brand: Combigan | $39.08–$39.15 per mL 3 packages, lowest to highest |
NADAC list of November 11, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Caplin Steriles Limited3 products
- Somerset Therapeutics, LLC3 products
- Gland Pharma Limited3 products
- Devatis, Inc.1 product
- Glenmark Pharmaceuticals Inc., USA1 product
- NorthStar RxLLC1 product
- Allergan, Inc.1 product
- Sandoz Inc1 product
- Alembic Pharmaceuticals Limited1 product
- Leading Pharma, LLC1 product
- Florida Pharmaceutical Products, LLC1 product
- Upsher-Smith Laboratories, LLC1 product
- Apotex Corp.1 product
- Armas Pharmaceuticals Inc.1 product
- Alembic Pharmaceuticals Inc.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA021398 COMBIGAN | Abbvie | October 30, 2007 | 3, latest March 17, 2026 2026: Labeling · 2015: Labeling · 2012: Labeling |
Generic approvals (10)
- ANDA091087Sandoz · April 4, 2022
- ANDA091442Apotex · April 20, 2022
- ANDA201949Regcon Holdings · October 4, 2022
- ANDA215598Upsher Smith Labs · December 12, 2022
- ANDA215230Alembic · August 25, 2023
- ANDA214987Glenmark Pharms Ltd · May 16, 2024
- ANDA216114Somerset · September 10, 2024
- ANDA219093Caplin · February 25, 2025
- ANDA219166Gland · June 11, 2026
- ANDA217934Saba Ilac Sanayive · July 1, 2026
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
March 5, 2026 · Class II · Ongoing · D-0407-2026
Lack of Assurance of Sterility
Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution 0.2%/0.5%*, 5 mL, Rx Only, Sterile, Apotex Corp. Manufactured for: Apotex Corp., Weston, FL 33326, NDC 60505-0589-1. — Apotex Corp.
-
September 5, 2025 · Class II · Ongoing · D-0676-2025
Lack of Assurance of Sterility; atypical weight loss due to improper bottle sealing leading to potential sterility concerns
Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution, 0.2%/0.5%, a) 5 mL and b) 10 mL, Rx Only, Sterile, Manufactured by: Apotex Inc., Richmond Hill, Ontario, Canada, L4C 5H2, Manufactured for: Apotex Corp., Weston, — Apotex Corp.
-
May 28, 2025 · Class II · Ongoing · D-0496-2025
Lack of Assurance of Sterility
Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution, 0.2%/0.5%, 15 mL, Rx Only, Sterile, Manufactured by: Apotex Inc., Toronto, Ontario, Canada, M9L 1T9, Manufactured for: Apotex Corp., Weston, FL 33326, NDC 60505-0 — Apotex Corp.
-
March 19, 2019 · Class II · Terminated · D-1056-2019
cGMP Deviations
Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% 5 mL bottles, Rx only, Allergan, Inc. Irvine, CA 92612 U.S.A. NDC 0023-9211-05 — Allergan Sales, LLC
-
October 19, 2017 · Class III · Terminated · D-0077-2018
Failed Impurities/Degradation Specifications.
Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, Rx only, packaged in a) 2.5 mL NDC# 0023-9211-03; b) 5 mL (NDC# 0023-9211-05); c) 10 mL (NDC# 0023-9211-10); d) 15 mL (NDC# 0023-9211-15) bot — Allergan Sales, LLC
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| RxCUI (RxNorm) | 861635, 861637 |
|---|---|
| SPL set ID of the quoted label | 038cf2ba-ad08-4981-a3cc-bff0e4ba5dfb |
| FDA labels (SPL) | 15 |
| FDA applications | NDA021398, 10 ANDA |
| Active ingredients (FDA) | BRIMONIDINE / TIMOLOL |
Next steps
- Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
- Latest FDA drug recallsAll medicines, newest first
- CombiganBrand page: products, maker and price
- Caplin Steriles LimitedMaker or distributor
- Somerset Therapeutics, LLCMaker or distributor
- Gland Pharma LimitedMaker or distributor
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Brimonidine Tartrate and Timolol maleate Ophthalmic Solution, Gland Pharma Limited, effective June 16, 2026; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →